Please assess the completion status of the following clinical trial:

Trial Title: Effects of IL-1 Beta on the HPA-axis in Obese Persons

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80 years~* BMI \>30kg/m2 and at least 1 manifestations of the metabolic syndrome (i.e. diabetes/ prediabetes, hypertension, dyslipidemia)~* Willingness to use contraceptive measures adequate to prevent becoming pregnant~Exclusion Criteria:~* Medication with glucocorticosteroids~* Known Cushing Syndrome~* Pregnancy or breast feeding~* Clinical signs of infection in the week before inclusion or history of a severe infection during the last 2 months~* Hematologic disease (leukocyte count \< 1.5x109/l, hemoglobin \<11 g/dl, platelets \<100 x 103/ul)~* Kidney disease (creatinine-clearance \< 30ml/min))~* Liver disease (transaminases \>4x upper normal range)~* Active carcinoma~* History of tuberculosis~* Alcohol consumption \>40g/d for men, \>30g/d for women~* Known allergy towards anakinra~* Subject refusing or unable to give written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): Anakinra 100mg s.c. x 5

Based on this trial design, predict the completion outcome and termination type (if applicable).